M&A Deal Summary

Taro Pharmaceuticals Acquires Zalicus Pharmaceuticals

On October 14, 2015, Taro Pharmaceuticals acquired life science company Zalicus Pharmaceuticals from Epirus Biopharmaceuticals for 4M USD

Acquisition Highlights
  • This is Taro Pharmaceuticals’ 1st transaction in the Life Science sector.
  • This is Taro Pharmaceuticals’ largest (disclosed) transaction.
  • This is Taro Pharmaceuticals’ 1st transaction in Canada.
  • This is Taro Pharmaceuticals’ 1st transaction in British Columbia.

M&A Deal Summary
Date 2015-10-14
Target Zalicus Pharmaceuticals
Sector Life Science
Buyer(s) Taro Pharmaceuticals
Sellers(s) Epirus Biopharmaceuticals
Deal Type Divestiture
Deal Value 4M USD

Target

Zalicus Pharmaceuticals

Vancouver, British Columbia, Canada
Zalicus Pharmaceuticals Ltd. is a pharmaceutical company developer of biosimilar drugs.

Search 198,123 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Taro Pharmaceuticals

Brampton, Ontario, Canada
Category Company
Founded 1984
Sector Life Science
DESCRIPTION

Taro Pharmaceuticals, Inc. is a pharmaceutical company.

DEAL STATS #
Overall 1 of 1
Sector (Life Science) 1 of 1
Type (Divestiture) 1 of 1
State (British Columbia) 1 of 1
Country (Canada) 1 of 1
Year (2015) 1 of 1
Size (of disclosed) 1 of 1

Seller(S) 1

SELLER

Epirus Biopharmaceuticals

Boston, Massachusetts, United States
Category Company
Founded 2011
Sector Life Science
Employees73
DESCRIPTION

Epirus Biopharmaceuticals is a biopharmaceutical company, develops, manufactures and commercializes biosimilar therapeutics worldwide. Epirus Biopharmaceuticals is based in Boston, Massachusetts.

DEAL STATS #
Overall 1 of 1
Sector (Life Science) 1 of 1
Type (Divestiture) 1 of 1
State (British Columbia) 1 of 1
Country (Canada) 1 of 1
Year (2015) 1 of 1
Size (of disclosed) 1 of 1
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2015-09-09 Bioceros BV

Utrecht, Netherlands

Bioceros BV is a biopharmaceutical R&D company focused on the development of mAbs and generation of GMP-ready cell lines. Over the past decade, Bioceros has developed numerous biosimilar cell lines from its proprietary, well-characterized CHO platform (CHOBC®)i.

Buy $14M
Mergr

Product

Company

Legal